Advocacy group accuses FDA neuro chief Billy Dunn of misconduct in controversial Biogen review, demands a purge and federal probe
Public Citizen has never held back when it comes to criticizing the FDA. But today, they’re taking their typical attack mode and ratcheting it up to a whole new level.
The consumer advocacy group has singled out Billy Dunn and his crew of neuro specialists at the FDA for an “inappropriate close collaboration with Biogen” in the way they handled their review of Biogen’s controversial Alzheimer’s drug aducanumab. From their perspective, the performance of Dunn’s group is another example of “regulatory capture” in which they were co-opted by a company in the same way the FAA was accused of after back-to-back crashes last year involving Boeing’s 737 MAX that killed hundreds of people.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
